🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14 results for “Elan Pharma International” Clear

  1. Atropine Eye Drops, Solution (0.05% w/v), Atropine Eye Drops, Solution (0.025% w/v), The placebo consists of the same composition as the atropine eye drops except for the active substance.

    Elan Pharma International

    Myopia

    phase 3 small molecule active

    1 trial

  2. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  3. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  4. INEBILIZUMAB, 10 mL (nominal) solution containing 10 mM histidine/histidine hydrochloride, 75 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.02% (w/v) polysorbate 80, pH 6.0

    Elan Pharma International

    Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).

    phase 3 small molecule active

    1 trial

  5. INEBILIZUMAB, 10 mL (nominal) solution containing 20 mM histidine/histidine hydrochloride, 70 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.01% (w/v) polysorbate 80

    Elan Pharma International

    Immunoglobulin G4-related disease (IgG4-RD)

    phase 3 small molecule active

    1 trial

  6. Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc, Fipaxalparant

    Elan Pharma International

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  7. Fipaxalparant

    Elan Pharma International

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  8. Fipaxalparant, Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc

    Elan Pharma International

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  9. HZN-1116, HZN-1116, commercially available 0.9% (w/v) saline solution intended for SC administration, HZN-1116

    Elan Pharma International

    Sjögren’s Syndrome

    phase 2 small molecule active

    1 trial

  10. INEBILIZUMAB

    Elan Pharma International

    Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])

    phase 2 small molecule active

    1 trial

  11. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  12. Placebo: Normal Saline - Solution for injection, Daxdilimab

    Elan Pharma International

    Primary Discoid Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  13. WVE-006

    Elan Pharma International

    Alpha-1 antitrypsin deficiency (AATD)

    phase 2 small molecule active

    1 trial

  14. A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity

    Elan Pharma International

    Adults Living with Overweight and Obesity

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources